title: Synergistic antiproliferative effect of the combination of natural human tumor necrosis factor-alpha and natural murine interferon-alpha/beta against colon-26 adenocarcinoma hepatic metastases in a murine model.
abstract: To prevent the development of hepatic metastases after surgery for colorectal cancer, it is important to inhibit the growth of any micrometastases which occur during the operation. We used a hepatic metastasis model in mice to investigate the effects of combination therapy with natural human tumor necrosis factor-alpha (nHuTNF-alpha) and natural murine interferon-alpha/beta (nMuIFN-alpha/beta). Decreased formation of hepatic metastases by murine colon-26 carcinoma was recognized following a single injection of nHuTNF-alpha, nMuIFN-alpha/beta, or both. These inhibitory effects were synergistic. NK activity was also measured, because notaral lerller cells not only have an anti-tumor effect but are also a representative of the host immune system. Both nHuTNF-alpha and nMuIFN-alpha/beta were able to activate NK cells, and the combination of the cytokines more significantly augmented NK activity. The in vivo elevation of NK activity induced by nHuTNF-alpha, nMuIFN-alpha/beta, or their combination may be one of the mechanisms of their antiproliferative effect on experimental hepatic metastases of murine colon-26 carcinoma.
authors: First Department of Surgery, Okayama University Medical School, Japan.
authors: E
authors: E
authors: Sanada
authors: S
authors: S
authors: Fuchimoto
authors: K
authors: K
authors: Orita
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary / Q000628:therapy*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000628:therapy*; D004195:Disease Models, Animal; D004357:Drug Synergism; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000556:secondary / Q000628:therapy*; D051379:Mice; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
chemical_list: D007370:Interferon Type I; D014409:Tumor Necrosis Factor-alpha